BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007;25:7041-6. [DOI: 10.1016/j.vaccine.2007.07.060] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Crawt L, Atkinson E, Tedcastle A, Pegg E, Dobly A, Wei C, Lei S, Ling P, Li C, Zheng J, Wang Y, Liqun H, Jorajuria S, Cozic G, Ugiyadi D, Kurniati N, Ochiai S, Miyazawa M, Someya Y, Nishihama T, Masafumi M, Westdijk J, Crowe S, Graaf MD, Kouiavskaia D, Chumakov K, Minor P, Cooper G, Rigsby P, Martin J; sIPV Study Group. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. The Journal of Infectious Diseases 2019. [DOI: 10.1093/infdis/jiz076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014;32:4938-44. [DOI: 10.1016/j.vaccine.2014.07.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
3 Westdijk J, Brugmans D, Martin J, Oever AV, Bakker WA, Levels L, Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011;29:3390-7. [DOI: 10.1016/j.vaccine.2011.02.085] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
4 Warda FF, Ahmed HES, Shafik NG, Mikhael CA, Abd-ElAziz HMG, Mohammed WA, Shosha EA. Application of equine herpesvirus-1 vaccine inactivated by both formaldehyde and binary ethylenimine in equine. Vet World 2021;14:1815-21. [PMID: 34475703 DOI: 10.14202/vetworld.2021.1815-1821] [Reference Citation Analysis]
5 Abd-Elghaffar AA, Rashed ME, Ali AE, Amin MA. In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine. Vaccines (Basel) 2020;8:E601. [PMID: 33066050 DOI: 10.3390/vaccines8040601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol 2014;5:365. [PMID: 25076945 DOI: 10.3389/fmicb.2014.00365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Schepp RM, Berbers GA, Ferreira JA, Reimerink JH, van der Klis FR. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus. Journal of Virological Methods 2017;241:15-23. [DOI: 10.1016/j.jviromet.2016.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis 2012;12:24. [PMID: 22280025 DOI: 10.1186/1471-2334-12-24] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Fan YC, Chiu HC, Chen LK, Chang GJ, Chiou SS. Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Negl Trop Dis 2015;9:e0004167. [PMID: 26495991 DOI: 10.1371/journal.pntd.0004167] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
11 Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. Vaccines. Elsevier; 2013. pp. 573-97. [DOI: 10.1016/b978-1-4557-0090-5.00034-3] [Cited by in Crossref: 25] [Article Influence: 3.1] [Reference Citation Analysis]
12 Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 2012;11:695-719. [PMID: 22873127 DOI: 10.1586/erv.12.38] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
13 Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 2014;10:635-44. [DOI: 10.1586/erv.11.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
14 Chen S, Cheng AC, Wang MS, Zhu DK, Jia RY, Luo QH, Liu F, Chen XY, Yang JL. Humoral and cellular immune responses in adult geese induced by an inactivated vaccine against new type gosling viral enteritis virus. Poult Sci 2010;89:2410-8. [PMID: 20952704 DOI: 10.3382/ps.2010-00958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Zhugunissov K, Zakarya K, Khairullin B, Orynbayev M, Abduraimov Y, Kassenov M, Sultankulova K, Kerimbayev A, Nurabayev S, Myrzakhmetova B, Nakhanov A, Nurpeisova A, Chervyakova O, Assanzhanova N, Burashev Y, Mambetaliyev M, Azanbekova M, Kopeyev S, Kozhabergenov N, Issabek A, Tuyskanova M, Kutumbetov L. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters. Front Microbiol 2021;12:720437. [PMID: 34646246 DOI: 10.3389/fmicb.2021.720437] [Reference Citation Analysis]
16 Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of formaldehyde inactivation on poliovirus. J Virol 2014;88:11955-64. [PMID: 25100844 DOI: 10.1128/JVI.01809-14] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
17 Ma L, Cai W, Sun M, Cun Y, Zhou J, Liu J, Hu W, Zhang X, Song S, Jiang S, Liao G. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats. Hum Vaccin Immunother 2016;12:3125-31. [PMID: 27558963 DOI: 10.1080/21645515.2016.1214347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Belanger JM, Raviv Y, Viard M, de la Cruz MJ, Nagashima K, Blumenthal R. Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1). Virology 2011;417:221-8. [PMID: 21726886 DOI: 10.1016/j.virol.2011.06.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Tobin GJ, Tobin JK, Gaidamakova EK, Wiggins TJ, Bushnell RV, Lee WM, Matrosova VY, Dollery SJ, Meeks HN, Kouiavskaia D, Chumakov K, Daly MJ. A novel gamma radiation-inactivated sabin-based polio vaccine. PLoS One 2020;15:e0228006. [PMID: 31999745 DOI: 10.1371/journal.pone.0228006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
20 Salmons B, Lim PY, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine 2018;36:6623-30. [PMID: 30293762 DOI: 10.1016/j.vaccine.2018.09.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008;47:1587-92. [PMID: 18990066 DOI: 10.1086/593310] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
22 Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11:609-28. [PMID: 22827246 DOI: 10.1586/erv.12.28] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
23 David SA, Volokhov DV, Ye Z, Chizhikov V. Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model. Appl Environ Microbiol 2010;76:2718-28. [PMID: 20228111 DOI: 10.1128/AEM.02776-09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
24 Belanger JM, Raviv Y, Viard M, Jason de la Cruz M, Nagashima K, Blumenthal R. Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1. Photochem Photobiol 2010;86:1099-108. [PMID: 20630026 DOI: 10.1111/j.1751-1097.2010.00780.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
25 Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29:7188-7196. [PMID: 21651934 DOI: 10.1016/j.vaccine.2011.05.079] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
26 Hankaniemi MM, Stone VM, Sioofy-Khojine AB, Heinimäki S, Marjomäki V, Hyöty H, Blazevic V, Laitinen OH, Flodström-Tullberg M, Hytönen VP. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine 2019;37:5962-71. [PMID: 31471148 DOI: 10.1016/j.vaccine.2019.08.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Shirato H, Someya Y, Ochiai M, Horiuchi Y, Takahashi M, Takeda N, Wakabayashi K, Ouchi Y, Ota Y, Tano Y, Abe S, Yamazaki S, Wakita T; sIPV Evaluation Group of NIID-Virology II. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32:5163-9. [PMID: 25090648 DOI: 10.1016/j.vaccine.2014.07.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hamidi A, Bakker WA. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal 2012;1:589-99. [PMID: 24236927 DOI: 10.4155/ppa.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
29 Huijuan Y, Xiaohu D, Ze L, Wei C, Jian Z, Lei M, Shaohui S, Weidong L, Guoyang L. Role of phenol red in the stabilization of the Sabin type 2 inactivated polio vaccine at various pH values. J Med Virol 2018;91:22-30. [DOI: 10.1002/jmv.25289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sato Y, Shiosaki K, Goto Y, Sonoda K, Kino Y. Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine. Biologicals 2013;41:184-9. [DOI: 10.1016/j.biologicals.2012.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
32 Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine AB, Marjomäki V, Hyöty H, Blazevic V, Flodström-Tullberg M, Hytönen VP, Laitinen OH. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Res 2019;171:104595. [PMID: 31491431 DOI: 10.1016/j.antiviral.2019.104595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Kim HJ, Hwang S, Lee S, Kwon Y, Park K, Park YJ, Bae GR, Lee SW, Jeong YS, Hyeon JY. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people. BMC Infect Dis 2015;15:164. [PMID: 25881203 DOI: 10.1186/s12879-015-0894-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]